Industry News
Pharmaceutical Industry News
Syngene: Transforming Monoclonal…
Syngene: Transforming Monoclonal Antibody Manufacturing for the Next Wave of Biologics
With the launch of a new branded…
With the launch of a new branded initiative, Bristol Myers Squibb is crafting a recipe for both ramping up its Cobenfy rollout and boosting schizophrenia awareness and education.
The FDA has adjusted the label of…
The FDA has adjusted the label of Johnson & Johnson and Legend Biotech’s Carvykti, warning patients and doctors that use of the multiple myeloma treatment could increase the risk an intestinal inflammatory disorder which can
Germany’s LTS—whose…
Germany's LTS—whose bread-and-butter business revolves around developing and manufacturing drug delivery systems—is paying an undisclosed sum to purchase U.S. CDMO Renaissance Lakewood, which itself specializes in nasals sprays and sterile dosage forms.
Halozyme scoured very broadly for…
Halozyme scoured very broadly for potential acquisitions in the drug delivery field before landing on Elektrofi, Halozyme CEO Helen Torley said during an interview on the sidelines of Fierce Biotech Week in Boston.
Trump Cuts a Deal With AstraZeneca to Lower Drug Prices
The president and top health officials acknowledged using the leverage of tariff threats to forge an agreement. Other companies are still in negotiations with the White House.
President Donald Trump has been…
President Donald Trump has been pressuring top drugmakers to get on board with his drug pricing agenda for months. Now, AstraZeneca is ready to comply, MSNBC reports.
The 2025 edition of Time’s…
The 2025 edition of Time’s annual “best inventions” list saw the magazine expand the docket from 200 to 300 innovations—more than 10% of which comprise medical devices, pharmaceuticals and other novel products in the healthcare
Auto-injector specialist Ypsomed…
Auto-injector specialist Ypsomed is hopping on the United States manufacturing bandwagon, investing 200 million Swiss francs ($248 million) to build a plant in Holly Springs, North Carolina. It will be the first U.S. facility for
The Senate has passed a new…
The Senate has passed a new version of the Biosecure Act as part of an amendment to the National Defense Authorization Act for the upcoming fiscal year. While similar to last year's edition, this amendment
AstraZeneca and Daiichi Sankyo are…
AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead in first-line triple-negative breast cancer. China's InnoCare agreed to out-license three autoimmune candidates to Zenas. Lupin plans to invest $250 million to build
Pelthos Therapeutics is seeking…
Pelthos Therapeutics is seeking mothers who don’t mess around to raise awareness about the treatment of molluscum contagiosum.
Pharma representatives who…
Pharma representatives who received an invite to the summit have reportedly expressed “consternation” over the concern that the event’s host and guest list imply that the White House wants drugmakers to work with BlinkRx.
AstraZeneca has broken ground on a…
AstraZeneca has broken ground on a $4.5 billion manufacturing facility near Charlottesville, Virginia, confirming a report about its location six weeks ago when state lawmakers approved an economic development package for the project.
Eli Lilly has committed to setting…
Eli Lilly has committed to setting a new standard for onscreen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.”
The FDA has approved Libtayo as…
The FDA has approved Libtayo as the first immunotherapy for adjuvant treatment of cutaneous squamous cell carcinoma. The nod applies to patients who are at a high risk of recurrence after surgery and radiation.
Lupin expects to invest a combined…
Lupin expects to invest a combined $250 million—covering R&D, infrastructure and capital expenditures over five years—to build a new pharmaceutical production plant in Coral Springs, Florida. The site will focus on the production of respiratory
Xspray has now received three FDA…
Xspray has now received three FDA complete response letters in as many years as it attempts to launch its Dasynoc, a leukemia med based on BMS' blockbuster Sprycel.
Phreesia’s Danielle Lynch…
Phreesia's Danielle Lynch discusses patient engagement at scale
Ferring plans to lay off 500…
Ferring plans to lay off 500 employees, or approximately 7% of its staff, as part of a streamlining effort, the company said in a brief statement.